ObsEva Announces Year End 2020 Financial Results and Business Update
ObsEva Announces Year End 2020 Financial Results and Business Update March 05, 2021 01:00 ET | Source: ObsEva SA ObsEva SA Plan-Les-Ouates Geneva, SWITZERLAND -Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for endometriosis: Readout from Phase 3 EDELWEISS 3 study expected in Q4:21- -Ebopiprant: Phase 2b dose ranging study planned to initiate in Q4:21 based on positive Phase 2a proof of concept- -Actively pursuing new indications and partnerships to maxi...